1-7 of 7
Leonard J. Appleman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

SWOG/NCI Phase II Dual Anti–CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer

Young Kwang Chae, Megan Othus, Sandip Pravin Patel, Kelly J. Wilkinson, Emily M. Whitman-Purves, Jayanthi Lea, John M. Schallenkamp, Nabil Adra, Leonard J. Appleman, Mitchell Alden, Jessica Thomes Pepin, John A. Ellerton, Andrew Poklepovic, Adam Walter, Murtuza M. Rampurwala, William R. Robinson, Hye Sung Kim, Liam IL-Young Chung, Christine M. McLeod, Gabby Lopez, Helen X. Chen, Elad Sharon, Howard Streicher, Christopher W. Ryan, Charles D. Blanke, Razelle Kurzrock
Journal: Clinical Cancer Research
Clin Cancer Res OF1–OF8.
https://doi.org/10.1158/1078-0432.CCR-24-0606
Published: 19 November 2024
View article titled, SWOG/NCI Phase II Dual Anti–CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer
Open the PDF for SWOG/NCI Phase II Dual Anti–CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma

Daniel P. Petrylak, Bernhard J. Eigl, Saby George, Elisabeth I. Heath, Sebastien J. Hotte, David D. Chism, Lisle M. Nabell, Joel Picus, Susanna Y. Cheng, Leonard J. Appleman, Guru P. Sonpavde, Alicia K. Morgans, Pourya Pourhosseini, Ruishan Wu, Laura Standley, Ruslan Croitoru, Evan Y. Yu
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (1): 63–73.
https://doi.org/10.1158/1078-0432.CCR-22-3627
Published: 05 January 2024
View article titled, Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Open the PDF for Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma in another window
Includes: Supplementary data
Journal Articles

A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer

Lawrence Fong, Michael J. Morris, Oliver Sartor, Celestia S. Higano, Lance Pagliaro, Ajjai Alva, Leonard J. Appleman, Winston Tan, Ulka Vaishampayan, Raphaelle Porcu, Darren Tayama, Edward E. Kadel, III, Kobe C. Yuen, Asim Datye, Andrew J. Armstrong, Daniel P. Petrylak
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (17): 4746–4756.
https://doi.org/10.1158/1078-0432.CCR-21-0063
Published: 01 September 2021
View article titled, A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer
Open the PDF for A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Autophagy Inhibition to Augment mTOR Inhibition: a Phase I/II Trial of Everolimus and Hydroxychloroquine in Patients with Previously Treated Renal Cell Carcinoma

Naomi B. Haas, Leonard J. Appleman, Mark Stein, Maryann Redlinger, Melissa Wilks, Xiaowei Xu, Angelique Onorati, Anusha Kalavacharla, Taehyong Kim, Chao Jie Zhen, Sabah Kadri, Jeremy P. Segal, Phyllis A. Gimotty, Lisa E. Davis, Ravi K. Amaravadi
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (7): 2080–2087.
https://doi.org/10.1158/1078-0432.CCR-18-2204
Published: 01 April 2019
View article titled, Autophagy Inhibition to Augment mTOR Inhibition: a Phase I/II Trial of Everolimus and Hydroxychloroquine in Patients with Previously Treated Renal Cell Carcinoma
Open the PDF for Autophagy Inhibition to Augment mTOR Inhibition: a Phase I/II Trial of Everolimus and Hydroxychloroquine in Patients with Previously Treated Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of DMS612, a Novel Bifunctional Alkylating Agent

Leonard J. Appleman, Sanjeeve Balasubramaniam, Robert A. Parise, Christine Bryla, Christophe E. Redon, Asako J. Nakamura, William M. Bonner, John J. Wright, Richard Piekarz, David R. Kohler, Yixing Jiang, Chandra P. Belani, Julie Eiseman, Edward Chu, Jan H. Beumer, Susan E. Bates
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (4): 721–729.
https://doi.org/10.1158/1078-0432.CCR-14-1333
Published: 16 February 2015
View article titled, A Phase I Study of DMS612, a Novel Bifunctional Alkylating Agent
Open the PDF for A Phase I Study of DMS612, a Novel Bifunctional Alkylating Agent in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2

Joseph Paul Eder, Geoffrey I. Shapiro, Leonard J. Appleman, Andrew X. Zhu, Dale Miles, Harold Keer, Belinda Cancilla, Felix Chu, Suzanne Hitchcock-Bryan, Laurie Sherman, Stewart McCallum, Elisabeth I. Heath, Scott A. Boerner, Patricia M. LoRusso
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (13): 3507–3516.
https://doi.org/10.1158/1078-0432.CCR-10-0574
Published: 01 July 2010
View article titled, A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2
Open the PDF for A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2 in another window
Journal Articles

Phase I and Pharmacokinetic Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously on Days 1, 3, and 5 Every 3 Weeks in Patients with Advanced Solid Tumors

Casey Cunningham, Leonard J. Appleman, Miora Kirvan-Visovatti, David P. Ryan, Eileen Regan, Svetislava Vukelja, Peter L. Bonate, Francis Ruvuna, Robert J. Fram, Antti Jekunen, Steve Weitman, Lisa A. Hammond, Joseph P. Eder, Jr.
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (21): 7825–7833.
https://doi.org/10.1158/1078-0432.CCR-05-0058
Published: 08 November 2005
View article titled, Phase I and Pharmacokinetic Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously on Days 1, 3, and 5 Every 3 Weeks in Patients with Advanced Solid Tumors
Open the PDF for Phase I and Pharmacokinetic Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously on Days 1, 3, and 5 Every 3 Weeks in Patients with Advanced Solid Tumors in another window